

AKT3 Blocking Peptide (N-term)
Synthetic peptide
Catalog # BP7030a**Specification****AKT3 Blocking Peptide (N-term) - Product Information**

Primary Accession [Q9Y243](#)
Other Accession [Q63484](#), [Q9WUA6](#)

AKT3 Blocking Peptide (N-term) - Additional Information

Gene ID 10000

Other Names

RAC-gamma serine/threonine-protein kinase, Protein kinase Akt-3, Protein kinase B gamma, PKB gamma, RAC-PK-gamma, STK-2, AKT3, PKBG

Target/Specificity

The synthetic peptide sequence is selected from aa 105-118 of HUMAN AKT3

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

AKT3 Blocking Peptide (N-term) - Protein Information

Name AKT3

Synonyms PKBG

Function

AKT3 is one of 3 closely related

AKT3 Blocking Peptide (N-term) - Background

AKT3 is a member of the AKT, also called PKB, serine/threonine protein kinase family. AKT kinases are known to be regulators of cell signaling in response to insulin and growth factors. They are involved in a wide variety of biological processes including cell proliferation, differentiation, apoptosis, tumorigenesis, as well as glycogen synthesis and glucose uptake. This kinase has been shown to be stimulated by platelet-derived growth factor (PDGF), insulin, and insulin-like growth factor 1 (IGF1).

AKT3 Blocking Peptide (N-term) - References

Xu, Z., et al., Biochem. Biophys. Res. Commun. 312(2):388-396 (2003).
Tiwari, G., et al., Mol. Cancer Res. 1(6):475-484 (2003).
Brozinick, J.T. Jr., et al., Diabetes 52(4):935-941 (2003).
Deregibus, M.C., et al., J. Biol. Chem. 277(28):25195-25202 (2002).
Brodbeck, D., et al., J. Biol. Chem. 276(31):29550-29558 (2001).

serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT3 is the least studied AKT isoform. It plays an important role in brain development and is crucial for the viability of malignant glioma cells. AKT3 isoform may also be the key molecule in up-regulation and down-regulation of MMP13 via IL13. Required for the coordination of mitochondrial biogenesis with growth factor-induced increases in cellular energy demands. Down-regulation by RNA interference reduces the expression of the phosphorylated form of BAD, resulting in the induction of caspase-dependent apoptosis.

Cellular Location

Nucleus. Cytoplasm. Membrane; Peripheral membrane protein

Note=Membrane-associated after cell stimulation leading to its translocation

Tissue Location

In adult tissues, it is highly expressed in brain, lung and kidney, but weakly in heart, testis and liver. In fetal tissues, it is highly expressed in heart, liver and brain and not at all in kidney

AKT3 Blocking Peptide (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)